I'm happy that things have gotten where they have, but I still see tremendous potential appreciation in the future. There are many, many ADCs in development by partners like Genentech/Roche which may yield milestones and royalties, if approved. Also, SGEN now also has multiple drugs in early stage trials that, if we get good data may help move things to the next level. I would also add that the new BLA filing for Adcetris puts a finite timeline on the possibility of label expansion, which is probably a catalyst for the current uptick. You have to keep the technology in mind as well, as it seems to really work, and appears to be able to be replicated. That is incredibly powerful and potentially very lucrative to this company.